Eric Burns - Vericel Corp Vice Relations

VCEL Stock  USD 58.62  0.49  0.83%   

Executive

Eric Burns is Vice Relations of Vericel Corp Ord
Address 64 Sidney Street, Cambridge, MA, United States, 02139
Phone617 588 5555
Webhttps://vcel.com

Vericel Corp Management Efficiency

The value of Return On Tangible Assets is estimated to slide to -0.0096. The value of Return On Capital Employed is expected to slide to -0.02. At this time, Vericel Corp's Intangible Assets are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 3.06 this year, although the value of Non Currrent Assets Other will most likely fall to about 732.5 K. Vericel Corp's management efficiency ratios could be used to measure how well Vericel Corp manages its routine affairs as well as how well it operates its assets and liabilities.
Vericel Corp Ord currently holds 88.14 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Vericel Corp Ord has a current ratio of 6.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vericel Corp's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Debra SieminskiTerns Pharmaceuticals
N/A
Diane WeiserCytokinetics
N/A
JD EsqIdeaya Biosciences
52
Marc CPACrinetics Pharmaceuticals
45
Matt YangCytokinetics
N/A
Melita JungTerns Pharmaceuticals
47
Scott HarrisTerns Pharmaceuticals
N/A
Jennifer SandozXencor Inc
N/A
Lucia CelonaDyne Therapeutics
58
Elly MDDay One Biopharmaceuticals
N/A
Jonathan MDDyne Therapeutics
39
Ariel HurleyBlueprint Medicines Corp
50
Andrew MDMerus BV
58
Brian JDRelay Therapeutics
50
Eric KowackXencor Inc
N/A
Kathleen FarrenMerus BV
N/A
Jeffrey JasperTerns Pharmaceuticals
N/A
Debra FeldmanDyne Therapeutics
53
Debra DursoBumpusBlueprint Medicines Corp
54
Eric TerhaerdtCytokinetics
N/A
Richard MBADyne Therapeutics
38
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Vericel operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 281 people. Vericel Corp Ord (VCEL) is traded on NASDAQ Exchange in USA. It is located in 64 Sidney Street, Cambridge, MA, United States, 02139 and employs 314 people. Vericel Corp is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Vericel Corp Ord Leadership Team

Elected by the shareholders, the Vericel Corp's board of directors comprises two types of representatives: Vericel Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vericel. The board's role is to monitor Vericel Corp's management team and ensure that shareholders' interests are well served. Vericel Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vericel Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonathan Siegal, VP Officer
Mike Gilligan, Senior Sales
Michael Halpin, Chief Officer
Patrick Fowler, Senior Strategy
Sean Flynn, Chief Officer
Joseph Mara, CFO Treasurer
MB FRCSEd, Chief Officer
Eric Burns, Vice Relations
Patrick Helfrich, Vice Strategy
Roland DeAngelis, Senior Operations
Heidi Hassen, Senior Resources
Dominick Esq, President CEO

Vericel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vericel Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Vericel Corp Ord is a strong investment it is important to analyze Vericel Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vericel Corp's future performance. For an informed investment choice regarding Vericel Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.045
Earnings Share
0.08
Revenue Per Share
4.685
Quarterly Revenue Growth
0.27
Return On Assets
(0)
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.